The immune organoid was created in the lab of Ankur Singh, assistant professor of mechanical and aerospace engineering, who applies engineering principles to the study and manipulation of the human immune system. The work was published online June 3 in Biomaterials and will appear later in print.
The synthetic organ is bio-inspired by secondary immune organs like the lymph node or spleen. It is made from gelatin-based biomaterials reinforced with nanoparticles and seeded with cells, and it mimics the anatomical microenvironment of lymphoid tissue. Like a real organ, the organoid converts B cells – which make antibodies that respond to infectious invaders – into germinal centers, which are clusters of B cells that activate, mature and mutate their antibody genes when the body is under attack. Germinal centers are a sign of infection and are not present in healthy immune organs.
The engineers have demonstrated how they can control this immune response in the organ and tune how quickly the B cells proliferate, get activated and change their antibody types. According to their paper, their 3-D organ outperforms existing 2-D cultures and can produce activated B cells up to 100 times faster.
The immune organ, made of a hydrogel, is a soft, nanocomposite biomaterial. The engineers reinforced the material with silicate nanoparticles to keep the structure from melting at the physiologically relevant temperature of 98.6 degrees.
The organ could lead to increased understanding of B cell functions, an area of study that typically relies on animal models to observe how the cells develop and mature.
What’s more, Singh said, the organ could be used to study specific infections and how the body produces antibodies to fight those infections – from Ebola to HIV.
“You can use our system to force the production of immunotherapeutics at much faster rates,” he said. Such a system also could be used to test toxic chemicals and environmental factors that contribute to infections or organ malfunctions.
The Latest on: Immune therapies
via Google News
The Latest on: Immune therapies
- Upfront Combo Therapy, vs Monotherapy, for Patients Not Previously Treated With a Biologic Agent Linked With Reduced Risk of IBD-Related Complicationson August 17, 2019 at 7:36 am
Although guidelines recommend inclusion of immune modulators in anti-tumor necrosis factor (TNF) initiation therapy for Crohn's disease (CD) or ulcerative colitis (UC), there are limited data on the ...
- Immune Cell Bank Bets on Future CAR T Successon August 16, 2019 at 1:08 pm
The field of T cell–based cancer therapies has rapidly blossomed in recent years, but at this point, scientists doubt the utility of stowing healthy T cells in a freezer, just in case. Cell Vault ...
- Psoriasis Action Month Focuses on New Therapieson August 16, 2019 at 11:05 am
Psoriasis biologics fight the disease by inhibiting cytokines, proteins secreted by the immune system that regulate immunity and inflammation. “Biologics are not a cure for psoriasis but they are a ...
- Immune Checkpoint Inhibitors in HL: Special Considerationson August 16, 2019 at 7:31 am
These so-called immune-related adverse events (irAEs) vary in incidence and the spectrum of affected organ systems depending on the agents used. The incidence of irAEs of any grade is variable and can ...
- HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapyon August 16, 2019 at 2:18 am
Moreover, data regarding the antiviral treatment for chronic hepatitis B (CHB ... HBV serological markers were measured using immune-enzymatic assays (Roche/Cobas Diagnostics, Rotkreuz, Switzerland).
- Gene Editing Market Size, Share, Growth, Trend, Therapy, Technology To Achieve An Excellent 18.30% CAGR During The Forecast 2023on August 16, 2019 at 1:59 am
Editing Genomes With The Bacterial Immune System Technology Has Emerged As A Powerful ... microorganism’s genetic engineering, and gene therapy. Based on the end-users, the gene editing market ...
- Immune-Activating Gene Therapy for Gliobastomaon August 15, 2019 at 3:19 pm
An inducible, tumor-localized gene therapy has been tested for the first time in glioblastoma patients. The two-part approach, which involves receiving an injection of an immune-activator gene into ...
- Four Distinguished Global Leaders Join the Human Vaccines Project's Efforts to Decode the Human Immune Systemon August 15, 2019 at 11:50 am
"The Human Vaccines Project is very pleased that these four accomplished leaders have embraced the Project's mission to address the next frontier in human health, the human immune system," says ...
- Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trialon August 15, 2019 at 10:30 am
Blood was collected from subjects at multiple time points, one week after each dose administration, and assayed for 450 different immune and tumor biomarkers. Treatment elicited a robust immune ...
- Immune cells drive gallstone formationon August 15, 2019 at 8:04 am
Although medicines do exist, they may require months or years of treatment to break up all gallstones. One hurdle limiting the development of new treatments is that scientists do not yet fully ...
via Bing News